Back to Journals » Breast Cancer: Targets and Therapy » Volume 12

Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

Authors Dillon PM, Brenin CM, Slingluff CL Jr

Received 25 January 2020

Accepted for publication 26 March 2020

Published 3 April 2020 Volume 2020:12 Pages 69—75


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Pranela Rameshwar

Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2

1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USA

Correspondence: Patrick M Dillon
Division of Hematology/Oncology, University of Virginia, Box 800716, Charlottesville, VA 22908, USA
Tel +1-434-982-1495
Fax +1-434-244-7534

Abstract: Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.

Keywords: vaccine, breast cancer, HER2, peptide, human

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]